A recently opened window of opportunity randomized controlled trial of Rivaroxaban in early breast cancer patients is exploring inhibition of the TF cofactor FXa in the oestrogen receptor negative subgroup of breast cancers, with biological endpoints including CSC activity. The gene discussed is TF; the disease is breast cancer.